SCHEMBL1877264

SCHEMBL1877264

Cc1ccc2cc(CBr)c(-c3ccccc3C)nc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAPT P10636 3/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PIK3CD O00329 1/20 0.40
ESR1 P03372 1/20 0.40
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 4/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
ERBB2 P04626 1/20 0.38
PIK3CG P48736 1/20 0.38
NQO2 P16083 1/20 0.38
CYP1A2 P05177 1/20 0.38
CTSD P07339 1/20 0.38
BACE1 P56817 1/20 0.38
HSD17B10 Q99714 2/20 0.37
ADORA2A P29274 1/20 0.36
MBNL1 Q9NR56 1/20 0.36
TSHR P16473 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL682461 0.87 PIK3CD (0.50) KMT2AMAPTRAB9ASMN1; SMN2PIK3CD
SCHEMBL1888145 0.86 AR (0.41) KMT2AMAPTPIK3CDALDH1A1ERBB2
SCHEMBL1888175 0.86 KMT2A (0.43) KMT2ANPSR1MAPTRAB9ASMN1; SMN2
SCHEMBL1884703 0.82 KDM4E (0.57) KMT2ANPSR1MAPTRAB9ASMN1; SMN2
SCHEMBL13647180 0.82 MBNL1 (0.53) KMT2ANPSR1MAPTRAB9ASMN1; SMN2
SCHEMBL1885090 0.81 MBNL1 (0.43) KMT2AMAPTRAB9ASMN1; SMN2PIK3CD
SCHEMBL1883204 0.78 MBNL1 (0.43) KMT2AMAPTPIK3CDALDH1A1KDM4E
SCHEMBL1598219 0.77 ATM (0.52) PIK3CDL3MBTL1
SCHEMBL1883148 0.74 ALDH1A1 (0.56) KMT2AMAPTRAB9ASMN1; SMN2ESR1
SCHEMBL1879719 0.74 PIK3CD (0.39) KMT2ANPSR1MAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399483-B2 Quinoxaline and quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2013-03-19 US disclosed
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA, S.A. (BE) 2011-05-05 US disclosed
EP-2231641-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2010-09-29 EP disclosed
WO-2009081105-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS PDXK, PDPK1, PIKFYVE KMT2A 1617/4885NPSR1 3587/4885MAPT 2318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.